We also demonstrated that silencing of EPB41L5 in 786-O cells significantly reduced their growth in vivo (that is, tumour volume) on treatment with Temsirolimus, as compared with the control Temsirolimus-treated 786-O cells, whereas this silencing did not notably affect the growth of 786-O cells in mice in the absence of the drug (Fig. 7c). The gene discussed is EPB41L5; the disease is neoplasm.